- PR Newswire•14 hours ago
Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness
DUBLIN, April 26, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients with excessive sleepiness associated with narcolepsy. Based on the preliminary safety analysis, the most commonly reported adverse events (AEs) in this study were generally consistent with those previously observed in the Phase 2 clinical studies evaluating JZP-110 in narcolepsy. "Excessive sleepiness in narcolepsy remains an important unmet medical need, and we believe that the statistically and clinically significant effect observed in this study indicates that JZP-110 could be an important treatment option for patients," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer of Jazz Pharmaceuticals. "Subject to completion of the data analysis and our regulatory discussions with FDA, we expect to submit the JZP-110 NDA for excessive sleepiness in obstructive sleep apnea and narcolepsy in late 2017.
- PR Newswire•2 days ago
DUBLIN, April 25, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after the close of the ...
- PR Newswire•3 days ago
Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
DUBLIN, April 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line efficacy results from the global, double-blind, placebo-controlled, randomized-withdrawal, ...
JAZZ : Summary for Jazz Pharmaceuticals plc - Yahoo Finance
Jazz Pharmaceuticals Public Limited Company (JAZZ)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||143.08 x 100|
|Day's Range||155.09 - 158.41|
|52 Week Range||95.80 - 158.41|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|